FDA panel weighs Moderna's first-in-class mRNA flu shot
TL;DR Summary
An FDA advisory panel is evaluating Moderna’s experimental mRNA-based influenza vaccine, a first-of-its-kind flu shot, with safety and efficacy data under review to determine if it could join future vaccination programs.
- FDA panel considers a first-of-its-kind flu vaccine using mRNA technology AP News
- FDA vaccine panel set to review Moderna mRNA flu shot The Hill
- mRNA-based influenza vaccine expands the B cell response breadth in humans Nature
- Quick takes: Moderna mRNA flu vaccine review, NIH award for genital herpes vaccine, malaria monoclonal antibody trial CIDRAP
- Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling Fierce Biotech
Reading Insights
Total Reads
1
Unique Readers
21
Time Saved
13 min
vs 14 min read
Condensed
99%
2,712 → 31 words
Want the full story? Read the original article
Read on AP News